Q4 2024 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002355
$120.7M
Reported value
11
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 055477103 | BCAX | Bicara Therapeutics Inc. | $38.4M | 31.8% | 2,204,650 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $34.8M | 28.8% | 13,072,340 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $23.9M | 19.8% | 1,975,203 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $7.8M | 6.46% | 1,184,636 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc | $5.1M | 4.25% | 653,223 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $3.7M | 3.06% | 2,249,123 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $3.5M | 2.90% | 526,357 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $1.8M | 1.48% | 1,788,160 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $1.4M | 1.14% | 843,750 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $271,123 | 0.22% | 321,502 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $57,792 | 0.05% | 251,270 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.